NCT06762730View on ClinicalTrials.gov

Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals

PHASE4RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2032

Conditions
HIV Infected IndividualsOsteopenia
Interventions
DRUG

Zoledronic Acid 5 mg/Bag 100 ml Inj

Zolendric acid will be provided to HIV naïve patients with documented osteopnia

Trial Locations (3)

9112001

RECRUITING

Hadassah Hebrew University Medical Center, Jerusalem

Unknown

NOT_YET_RECRUITING

Rambam Medical Center, Haifa

NOT_YET_RECRUITING

Sheba Medical Center, Ramat Gan

All Listed Sponsors
collaborator

Sheba Medical Center

OTHER_GOV

collaborator

Rambam Hospital, Haifa, Israel

UNKNOWN

lead

Hadassah Medical Organization

OTHER